CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
This marks the fourth acquisition by Corona Remedies from multinational corporations
Subscribe To Our Newsletter & Stay Updated